{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-226837","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.241393+00:00","generated_at":"2026-05-17T05:03:32.356016+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Catalyst Pharma announces $200M share repurchase program through Dec 2026","bullets":["Board authorized up to $200M share repurchase from Oct 1, 2025 to Dec 31, 2026.","Company had >$650M cash & equivalents and no funded debt as of June 30, 2025.","Repurchases may be via open market or privately negotiated; timing depends on stock price and conditions.","Program may be suspended or terminated anytime; no obligation to buy any specific amount.","Company plans to use existing cash on hand to fund the repurchase program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-226837","json":"https://secwatch.observer/filing/0001193125-25-226837.json","markdown":"https://secwatch.observer/filing/0001193125-25-226837.md","text":"https://secwatch.observer/filing/0001193125-25-226837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525226837/0001193125-25-226837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525226837/d118298d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:03:32.356016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}